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Danger Ahead: Watch Out
for Indirect Comparisons!*
Christopher P. Cannon, MD,† Payal Kohli, MD‡
Boston, Massachusetts
We have entered an exciting new era of anticoagulation—
with multiple new oral anticoagulants becoming available
for use as potential replacements for warfarin, the vitamin K
antagonist that has been the only oral agent available for 50
years! The most prominent of the indications for anticoag-
ulation is for stroke prevention in patients with atrial
fibrillation, where long-term, often life-long therapy is
needed in millions of patients. Two agents have already
been approved by the Food and Drug Administration
(FDA), and a third is anticipated later this year. There are
2 main classes of drugs that are undergoing testing or have
been tested in large randomized trials: direct thrombin
inhibitors (dabigatran [1]) and factor Xa inhibitors (rivar-
oxaban [2], apixaban [3], edoxaban [4]); in these trials, these
drugs are being compared with warfarin.
See page 738
Three large randomized trials (totaling over 50,000 pa-
tients with atrial fibrillation) comparing one of the newer
oral anticoagulants to warfarin have already been published.
Each new drug has shown equal or superior efficacy to
warfarin, suggesting that these agents offer excellent alter-
natives to warfarin for stroke prevention. But faced with
these growing new options, how do physicians choose
between them? Are there differences between the drugs in
their efficacy and/or safety that would help inform our
clinical decision to prescribe one over the other? Unfortu-
nately, no trials have been conducted (yet) that directly
compare one new agent versus another.
In this issue of the Journal, Lip et al. (5) have tried to
answer these questions by applying statistical methods to
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cause each trial had a common comparator arm, one could
assume similarity in outcomes of that arm and then look at
the relative benefit (or harm) that each drug displays versus
the standard arm. They have used the Bucher method to
compare hazard ratios of the new agent to the comparator to
try to determine the relative efficacy between the 2 newer
agents.
For such comparisons, however, we need to proceed with
extreme caution: attempts at indirect comparisons were
made among fibrinolytic agents—tissue plasminogen acti-
vator, streptokinase, and anistreplase—where relative reduc-
tions in mortality in placebo-controlled trials were 25%,
25%, and 50%, respectively (6–8). On the basis of these
results, one might be tempted to conclude that anistreplase
is superior, but in a direct comparison of these drugs in
ISIS-3 (Third International Study of Infarct Survival), no
difference in endpoints was seen (9). As such, indirect
comparisons can be misleading, and extreme caution should
be exercised when using such methods to draw definitive
conclusions.
After evaluating the efficacy of each new drug individu-
ally, Lip et al. (5) then went on to calculate a weighted
average of all the new agents combined to estimate the
relative benefit of “any new oral anticoagulant” versus
warfarin. This latter approach is akin to pooling or meta-
analysis of all the studies, and provides a reasonable over-
view of the “class effect.” For all the new oral anticoagulants,
they found that this class as a whole significantly reduced
the risk of: 1) stroke or systemic embolism by 21% (p 
.001); 2) stroke by 23% (p 0.001); 3) hemorrhagic stroke
y 53% (p 0.001); and 4) all-cause mortality by 12% (p
.001). In addition, major bleeding was lower for any new
ral anticoagulant by 13% (p  0.001) compared with
arfarin. This straightforward and statistically sound anal-
sis of the data strongly supports the use of the newer agents
ver warfarin, as a class.
For the indirect comparisons between individual agents,
owever, the picture remains a bit confusing. Lip et al.
eport a “significantly lower risk of stroke or systemic
mbolism (by 26%) for dabigatran 150 mg twice daily
ompared with rivaroxaban.” On the other hand, they
onclude “we found no profound significant differences in
fficacy between apixaban, and dabigatran (both doses) or
ivaroxaban.” They also report no significant difference in
yocardial infarction event rates among the 3 agents. Yet,
ithin the individual trials, the rate of myocardial infarction
as definitely higher with dabigatran (1), but not with
ither of the factor Xa inhibitors (2,3). These conflicting
esults lend support to the conclusion that such methods for
ndirect comparisons may not be the most accurate due to
everal sources of confounding.
The authors acknowledge that there are multiple limita-
ions in comparing different trials, despite the common
omparator arm—notably the patient population differs.
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Danger of Indirect Comparisons August 21, 2012:747–8Variations in the baseline risk of patients in 1 study could
influence the absolute rates of the endpoints in that study,
confounding the drug–drug comparison being studied. For
example, the ROCKET trial (Rivaroxaban-once daily, oral,
direct factor Xa inhibition compared with vitamin K antag-
onism for prevention of stroke and Embolism Trial in Atrial
Fibrillation) trial enrolled older patients with higher
CHADS2 (Congestive heart failure, Hypertension, Age,
iabetes, Prior Stroke) risk scores, and as such, would be
xpected to have higher rates of bleeding and stroke—which
ight influence the relative drug effect seen in this trial.
herefore, 2 variables would differ when comparing a
imilar endpoint between these 2 trials—the drug being
ested and the patient population—and it would be unclear
hether any apparent difference observed in the relative
fficacy could be attributed to the drug alone. Similarly, the
ptimal use of warfarin (as measured by the “time in
herapeutic range”) also differed between these trials, result-
ng in another possible source of confounding that could
nfluence the relative efficacy of the drugs when comparing
he trials.
Traditional metrics for determining efficacy derive di-
ectly from the results of the randomized trial. Indeed, this
s exactly what the FDA does in the prescribing insert: the
DA approves and lists only those findings and indications
hat were directly reported in the randomized trials. As
uch, we would find that dabigatran 150 mg twice daily
ignificantly reduced stroke or systemic embolism (and
ithin that endpoint, ischemic stroke alone), but with a
imilar rate of major bleeding to warfarin. The 110-mg dose
unfortunately not approved by the FDA) had similar
fficacy for stroke or systemic embolism but a lower risk of
ajor bleeding compared with warfarin (1). For apixaban,
ignificant reductions in stroke or systemic embolism, major
leeding, and mortality were seen (3). Rivaroxaban showed
imilar rates of stroke or systemic embolism and major
leeding versus warfarin (2). But whether apixaban and
abigatran 150 mg are superior to rivaroxaban cannot
eadily be concluded by comparing the relative efficacy of
ach agent versus comparator within its own respective trial.
e can say though that these 2 agents have been shown to
e superior for stroke prevention, and apixaban for mortality
eduction, whereas neither can be said for rivaroxaban.
So what are we to do? Should we use the indirect
omparisons put forth by Lip et al. (5) since that provides
he only comparative data we have? In general, the authorsppear to be saying that there are more similarities between
hese agents than differences, as has also been previously
oted by Mega (10). However, because of the statistical
imitations of such comparisons, although of some interest,
e feel the differences they report on some endpoints are
ot robust enough to be relied upon for the clinical care of
atients. Instead, we would turn to direct evidence from
rials and the indications put forth by the FDA to select the
ppropriate agent, at the dose tested, for use in the patient
opulation studied within the trial.
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